Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach

Medical Physics

Volumn 26, Issue 4, 1999, Pages 609-615

  Kissel, Jutta ^a   Port, Rüdiger E ^a   Zaers, Joachim ^a   Bellemann, Matthias E ^a   Strauss, Ludwig G ^a   Haberkorn, Uwe ^a   Brix, Gunnar ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Arterial input function; Pharmacokinetic modeling; Population approach; Position emission tomography

Indexed keywords

AMINO ACIDS; BLOOD VESSELS; METABOLISM; METADATA; PHARMACOKINETICS; SUPERSONIC AIRCRAFT;

ARTERIAL INPUT FUNCTION; BIOCHEMICAL TRANSFORMATION; COEFFICIENTS OF VARIATIONS; NONINVASIVE DETERMINATION; PHARMACOKINETIC MODEL; POPULATION APPROACH; POSITION EMISSION TOMOGRAPHY; RADIOACTIVITY CONCENTRATION;

POPULATION STATISTICS;

ALPHA FLUORO BETA ALANINE; ANTINEOPLASTIC AGENT; FLUORINE 18; FLUOROURACIL; TRACER;

ABDOMINAL AORTA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; HUMAN; KINETICS; LIVER METASTASIS; MALE; POPULATION MODEL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY;

EID: 0032916975     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.598560     Document Type: Article

References (35)

1. L. G. Strauss and P. S. Conti, "The application of PET in clinical oncology," J. Nucl. Med. 32, 623-684 (1991).
2. A. Dimitrakopoulou, L. G. Strauss, J. H. Clorius, H. Ostertag, P. Schlag, M. Heim, F. Oberdorfer, F. Helus, U. Haberkorn, and G. van Kaick, "Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma," J. Nucl. Med. 34, 1075-1081 (1993).
3. 18F]uracil positron emission tomography (PET)," Eur. J. Cancer 29A, 1682-1686 (1993).
4. 19F MRI: A comparative animal study," Nucl. Med. Biol. 23, 879-906 (1996).
5. S. C. Huang and M. E. Phelps, "Principles of tracer kinetic modeling in positron emission tomography and autoradiography," in Positron Emission Tomography and Autoradiography, edited by M. E. Phelps, J. C. Mazziotta, and H. R. Schelbert (Raven, New York, 1986) pp. 287-346.
6. G. Di Chiro and R. A. Brooks, "PET quantitation: Blessing and curse," J. Nucl. Med. 29, 1603-1604 (1988).
7. I. N. Weinberg et al., "Validation of PET-acquired input functions for cardiac studies," J. Nucl. Med. 29, 241-247 (1988).
8. S. S. Gambhir, S. C. Huang, W. M. Digby, H. R. Schelbert, and M. E. Phelps, "An new method for partial volume spillover correction in cardiac PET scans," J. Nucl. Med. 30, 824-825 (1989).
9. G. Germano, B. C. Chen, S. C. Huang, S. S. Gambhir, E. J. Hoffman, and M. E. Phelps, "Use of the abdominal aorta for arterial input function determination in hepatic and renal studies," J. Nucl. Med. 33, 613-620 (1992).
10. S. Rajeswaran, D. Bailey, S. Hume, T. Jones, and D. Townsend, "2D and 3D imaging of small animals and the human radial artery with a high resolution detector for PET," Conference Record of the 1990 IEEE Nuclear Science Symposium, Volume II, 1990, pp. 1308-1312.
11. J. Correia, "A bloody future for clinical PET?" J. Nucl. Med. 33, 620-622 (1992).
12. S. Takihawa, V. Dhawan, P. Spetsieris, W. Robeson, T. Chaly, R. Dahl, D. Margouleff, and D. Eidelberg, "Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve," Radiology 188, 131-136 (1993).
13. H. M. Wu, S. C. Huang, V. Allada, P. J. Wolfenden, H. R. Schelbert, M. E. Phelps, and C. K. Koh, "Derivation of input function from FDG-PET studies in small hearts," J. Nucl. Med. 37, 1717-1722 (1996).
14. L. B. Sheiner, B. Rosenberg, and K. L. Melom, "Modeling of individual pharmacokinetics for computer-aided drug dosage," Comput. Biomed. Res. 5, 41-479 (1972).
15. J. L. Steimer, S. Vozeh, A. Racine-Poon, N. Holford, and R. O'Neill, "The population approach: Rationale, methods, and applications in clinical pharmacology and drug development," Pharmacokinetics of Drugs, edited by P. G. Welling and L. P. Balent (Springer-Verlag, Berlin, 1994), pp. 405-443.
16. C. Heidelberger, N. K. Chaudhuri, P. Danneberg, D. Mooren, L. Criesbach, R. Duschinsky, R. J. Schnitzer, E. Pleven, and J. Scheiner, "Fluorinated pyrimidines, a new class of tumour-inhibitory compounds," Nature (London) 179, 663-666 (1957).
17. N. Kemeny, "The systemic chemotherapy of hepatic metastases," Semin. Oncol. 10, 148-158 (1983).
18. S. L. Beal and L. B. Sheiner, NONMEM user's-guide. NONMEM Project Group, University of California, San Francisco, 1992.
19. F. Oberdorfer, E. Hofmann, and W. Maier-Borst, "Preparation of 18 F-labeled 5-fluorouracil of very high purity," J. Lab. Comps. Radiopharm 27, 137-145 (1989).
20. H. Hoverath, W. K. Kübler, H. Ostertag, J. Doll, S. I. Ziegler, M. V. Knopp, and W. J. Lorenz, "Scatter correction in the transaxial slices of a whole-body positron emission tomograph," Phys. Med. Biol. 38, 717-728 (1993).
21. H. Ostertag, W. K. Kübler, J. Doll, and W. J. Lorenz, "Measured attenuation correction methods," Eur. J. Nucl. Med. 15, 722-726 (1989).
22. L. A. Shepp and Y. Vardi, "Maximum likelihood reconstruction for emission tomography," IEEE Trans. Med. Imaging 1, 113-122 (1982).
23. R. M. Lewitt and G. Muehllehner, "Accelerated iterative reconstruction for positron emission tomography based on the EM algorithm for maximum likelihood estimation," IEEE Trans. Med. Imaging 5, 16-22 (1986).
24. G. Brix, J. Doll, M. E. Bellemann, H. Trojan, U. Haberkorn, P. Schmidlin, and H. J. Ostertag, "Use of scanner characteristics in iterative imaging reconstruction for high-resolution positron emission tomography studies of small animals," Eur. J. Nucl. Med. 24, 779-786 (1997).
25. 18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma," Cancer Res. 57, 3415-3423 (1997).
26. J. L.-S. Au, J. S. Walker, and Y. Rustum, "Pharmacokinetic studies of 5-fluorouracil and 5′-deoxy-5-fluorouridine in rats," J. Pharmacol. Exp. Ther. 227, 174-180 (1983).
27. R. S. Bourke, C. R. West, G. Ched, and D. B. Tower, "Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate," Cancer Res. 33, 1735-1746 (1973).
28. 19F MR imaging," Magn. Reson. Med. 34, 302-307 (1995).
29. W. A. Ritschel, Handbook of Basic Pharmacokinetics (Drug Intelligence Publications, Hamilton, 1992), p. 134.
30. D. H. van Thiel, N. G. Hagler, R. R. Schade, M. L. Skolnik, A. Pollit Heyl, E. Rosenblum, J. S. Gavaler, and R. J. Penkrot, "In vivo hepatic volume determination using sonography and computed tomo-graphy," Amer. Gastroentherol. Assoc. 88, 1812-1817 (1985).
31. D. duBois and E. F. duBois, "A formula to estimate the approximate surface area in height and weight be known," Arch. Intern. Med. 17, 863-871 (1916).
32. H. DeLand and W. North, "Relationship between liver size and body size," Radiology 91, 1195-1198 (1968).
33. L. B. Sheiner, "Modeling pharmacokinetic/pharmacodynamic variability," in Variability in Drug Therapy: Description, Estimation, and Control, edited by M. Rowland, L. B. Sheiner, and J. L. Steimer (Raven, New York), pp. 51-64.
34. L. B. Sheiner, B. Rosenberg, and V. V. Marathe, "Estimation of population characteristics of pharmacokinetic parameters from routine clinical data," J. Pharmacokinet. Biopharm. 5, 445-479 (1977).
35. Y. M. El Sayed and W. Sadee, "The fluoropyrimidines," in Pharmacokinetics of Anticancer Agents in Humans, edited by M. M. Ames, G. Powis, and J. S. Kovach (Elsevier, 1983), pp. 209-227.